AI assistant
aTYR PHARMA INC — Director's Dealing 2023
May 19, 2023
34337_dirs_2023-05-19_11bb434a-3c74-4425-a0da-67f1179a75ef.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2023-05-17
Reporting Person: COUGHLIN TIMOTHY (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-05-17 | Common Stock | G | 6000 | $0.00 | Disposed | 0 | Direct |
| 2023-05-17 | Common Stock | G | 6000 | $0.00 | Acquired | 6000 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-05-17 | Stock Option (right to buy) | $2.52 | A | 12000 | Acquired | 2033-05-17 | Common Stock (12000) | Direct |
Footnotes
F1: These shares are owned by the Coughlin Family Trust u/a DTD 12/07/2006. The Reporting Person and his spouse serve as co-trustees of the Coughlin Family Trust u/a DTD 12/07/2006. The Reporting Person may be deemed to be the beneficial owner of the securities held by the Coughlin Family Trust u/a DTD 12/07/2006.
F2: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 17, 2024 or (ii) the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.